A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
← catalyst calendarNCT07029711 · readout in 105 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
208actual
Sites
80
Countries
China, Czechia, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-31 | actual | When the study began enrolling |
| Primary completion | 2026-12-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-06 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Severe Alopecia Areata
Interventions
- Drug: Ritlecitinib higher dose — also filed as Active Treatment
- Drug: Ritlecitinib lower dose — also filed as Active Treatment
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFFor US and Countries Following US Analysis Plan: Response based on achieving an absolute Severity of Alopecia Tool (SALT) score ≤20.
measured Week 24
For EU/UK and Countries Following EU/UK Analysis Plan: Response based on achieving an absolute SALT score ≤10.
measured Week 24
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed